Pelareorep

Drug Profile

Pelareorep

Alternative Names: PO-BB0209; REOLYSIN; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus

Latest Information Update: 01 Jun 2017

Price : $50

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fallopian tube cancer; Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma; Solid tumours
  • Preclinical Hepatocellular carcinoma; Viral hepatitis

Most Recent Events

  • 23 May 2017 Oncolytics Biotech plans a registration trial in Breast cancer (Metastatic disease), and trials in solid and haematological malignancies (Combination therapy)
  • 17 May 2017 Safety and efficacy data from phase Ib REO 024 trial in Pancreatic cancer released by Oncolytics Biotech
  • 08 May 2017 Pelareorep receives Fast track status from the US FDA for Breast cancer (Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top